Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

Background: Targeted systemic therapies, including abrocitinib, baricitinib, dupilumab, tralokinumab and upadacitinib, are new treatments for moderate to severe atopic dermatitis (AD). We evaluated the efficacy and the costs of these targeted systemic therapies in the treatment of adult patients wit...

Full description

Bibliographic Details
Main Authors:	Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio
Format:	Article
Language:	English
Published:	AboutScience Srl 2024-02-01
Series:	Global & Regional Health Technology Assessment
Subjects:	Cost per NNT Upadacitinib EASI-75 EASI-90 Italian NHS Atopic dermatitis
Online Access:	https://journals.aboutscience.eu/index.php/grhta/article/view/2728

Similar Items

Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy
by: Luca Stingeni, et al.
Published: (2025-03-01)

Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis
by: Flavio Caprioli, et al.
Published: (2024-03-01)

Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
by: Stamatios Gregoriou, et al.
Published: (2025-01-01)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
by: Luigi Gargiulo, et al.
Published: (2023-12-01)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01)

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
by: Roberto Caporali, et al.
Published: (2021-07-01)

Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre Retrospective Study
by: Michela Ortoncelli, et al.
Published: (2023-11-01)

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis
by: S. K. Zyryanov, et al.
Published: (2023-07-01)

Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
by: Ana Batalla, et al.
Published: (2023-09-01)

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis
by: Takeshi Nakahara, et al.
Published: (2024-10-01)

Impact of wearing Comfiknit Atopic Eczema® T‐shirts on patients with atopic dermatitis: An open‐label pilot study
by: Naoko Hattori, et al.
Published: (2023-10-01)

Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies
by: Claudia Paganini, et al.
Published: (2025-03-01)

A Case of Upadacitinib-Associated Ileus Secondary to Psoriasis Induced by Treatment of Atopic Dermatitis with Dupilumab
by: Liu X, et al.
Published: (2024-12-01)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
by: Hagino T, et al.
Published: (2023-11-01)

The Relationship between the Severity of Atopic Dermatitis and Sleep Quality in Widya Mandala Surabaya Catholic University Teaching Hospital Patients
by: Caecilia Elva, et al.
Published: (2024-11-01)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
by: Emily Seale, MPH, et al.
Published: (2023-06-01)

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
by: Steven J Edwards, et al.
Published: (2024-01-01)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
by: Teresa Grieco, et al.
Published: (2023-03-01)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
by: Yuliya Lytvyn, et al.
Published: (2022-11-01)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
by: Ibba L, et al.
Published: (2024-03-01)

Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases
by: Makoto Ito, et al.
Published: (2023-10-01)

Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis
by: Teng Y, et al.
Published: (2024-11-01)

Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis
by: Jacob P. Thyssen, et al.
Published: (2023-12-01)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib
by: Takeshi Koga, et al.
Published: (2024-08-01)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
by: Miguel Nogueira, et al.
Published: (2021-10-01)

Real-World Experience of Upadacitinib Dosing Reduction in Patients With Moderate Atopic Dermatitis: A Case Series Study in Taiwan
by: Yang-Yi Chen, et al.
Published: (2024-07-01)

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks
by: Teppei Hagino, et al.
Published: (2024-04-01)

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis
by: Jonathan I. Silverberg, et al.
Published: (2023-09-01)

Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
by: Mara Giavina-Bianchi, MD, PhD, et al.
Published: (2024-08-01)

A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children
by: Amal A. Mohamed, et al.
Published: (2023-09-01)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
by: Teppei Hagino, et al.
Published: (2024-04-01)

The therapeutic effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on chemically induced atopic dermatitis
by: Su-Hyun Shin, et al.
Published: (2024-10-01)

Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials
by: Hannah Penton, et al.
Published: (2023-09-01)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023-12-01)

Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review
by: Angela Ayen-Rodríguez, et al.
Published: (2022-07-01)

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
by: Andrew Blauvelt, et al.
Published: (2024-08-01)

A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis
by: Yoshihito Mima, et al.
Published: (2024-06-01)

Treatment of atopic dermatitis with upadacitinib: adcare single center experience
by: Daria S. Fomina, et al.
Published: (2024-04-01)